Natixis’s Zosano Pharma Corporation ZSAN Stock Holding History

Natixis’s Portfolio ZSAN Stock Details ZSAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-849	Closed	-$21K	–	1400
2021 Q3	$21K	Buy	+849	New	+$22K	﹤0.01%	1180

Other funds holding ZSAN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Natixis's ZSAN Position: Q4 2021 in Review

Natixis sold out of Zosano Pharma Corporation (ZSAN) in Q4 2021, closing a stake of 849 shares — an estimated $21K sold.

Natixis first reported a position in ZSAN in Q3 2021 and held it in 1 quarter. The position peaked at $21K in Q3 2021. 32 funds tracked by Wall St. Rank hold ZSAN as of Q4 2021.

Natixis reported no remaining Zosano Pharma Corporation position as of Q4 2021 after selling out during the quarter.
Natixis sold 849 Zosano Pharma Corporation shares in Q4 2021, an estimated $21K.
Natixis first reported a position in Zosano Pharma Corporation in Q3 2021 and held it in 1 quarter.
Natixis's Zosano Pharma Corporation position peaked at $21K in Q3 2021.
32 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q4 2021.

Based on Natixis's 13F filing for Q4 2021, filed 14 Feb 2022.